three lymphocyte function tests. It would seem that the cellular immune response to an unrelated organism is not impaired in patients with herpetic infection and that the defects in macrophage migration inhibition activity and lymphocyte cytotoxicity are confined to H. hominis type 1 antigen. Long-term sequential studies will be pursued to test the hypothesis that impaired macrophage migration inhibition and lymphocyte cytotoxicity responses in the presence of a positive lymphocyte transformation and antibody reactions are responsible for recurrent herpetic infection.
Introduction Trimethoprim (TMP) became available for general use in medicine three years ago. It is a synthetic substance which inhibits the enzyme dihydrofolate reductase, necessary for the essential synthesis by bacteria of folinates, and it acts synergistically with sulphonamides, whose antibacterial effect is on an earlier stage in the same synthetic pathway (Hitchings, 1969) . Therapeutic preparations of trimethoprim are always put up in combination with a sulphonamide (Su) . The rationale for this is to make use of their synergistic antibacterial effects and at the same time prevent the emergence of mutant bacteria resistant to either drug (Bushby, 1969 (Gruneberg and Kolbe, 1969; Reeves et al., 1969) . Sulphonamide resistance is not uncommon in bacteria causing urinary infection (Williams and Leigh, 1966; Gruneberg, 1971; Shaw et al., 1972) . The incidence of resistance to trimethoprim is low; it is currently found, in our experience, in about 1% of urinary infections with Escherichia coli (Gruneberg, 1971) .
We report here the isolation from infected urines of bacteria highly resistant to both trimethoprim and sulphonamide in which the resistances were determined by transmissible R factors.
Materials and Methods
Bacteria.-Strains of Enterobacteriaceae, highly resistant to trimethoprim, were collected by Dr. E. Joan Stokes, Miss Pamela Waterworth, and R.N.G. from clinical material sent to the diagnostic laboratories at University College Hospital. Antibiotic sensitivity tests were made in the first instance by a disc diffusion method in which the size of zone given with the test strain is compared with that given using a standard sensitive strain (Stokes, 1968) . Sulphonamide and trimethoprim sensitivity tests were performed separately on a medium free of inhibitors. There were five cultures of E. coli whose minimal inhibitory concentration (M.I.C.) for trimethoprim was 16 ,ug/ml or more, all resistant also to sulphonamide and one of them to tetracycline. There were three cultures of Klebsiella spp. and one of Enterobacter aerogenes, all resistant to ampicillin, trimethoprim (M.I.C. 32 ptg/ml or more), and sulphonamide, and with various patterns of resistance to streptomycin (S), tetracycline (T), chloramphenicol (C), nalidixic acid, and nitrofurantoin. One further trimethoprim-sulphonamide-resistant E. coli was isolated subsequently (see below).
Minimal Inhibitory Concentrations.-Small inocula (broth cultures diluted sufficiently to give isolated colonies) were streaked on plates lacking trimethoprim-sulphonamide inhibitor (Waterworth, 1969) and containing serial dilutions of drug.
The M.I.C. was taken as the lowest concentration which prevented visible growth.
Resistance Transfer.-The 10 trimethoprim-resistant cultures were examined for R factors by M.P.F. and N.D. Each was grown in mixed broth culture with a nalidixic-acid-resistant E. coli recipient and the mixtures were plated on a selective medium (not containing sulphonamide-trimethoprim inhibitor) incorporating nalidixic acid 50 Dtg/ml and trimethoprim 5 jig/ml.
The recipient was E. coli K12 J62-1-non-lactose fermenting, nutritionally exacting, and sensitive to antibacterials other than nalidixic acid. Neither donor nor recipient grew on the selective medium. Colonies developing from the mixed cultures were purified, identified as E. coli K12 by their biochemical and nutritional characteristics, and tested for sensitivity to a range of antibacterial drugs including trimethoprim. In some experiments selection was made with sulphonamide or other drug to which the donor was resistant instead of trimethoprim. Where the K12 recipient had acquired resistance during growth in mixed culture it was tested for the ability to transfer that resistance to other distinguishable sublines of E. coli K12 and in one instance to Salmonella typhimurium WM 0024. When an R factor was thus detected it was transferred into a line of K12 carrying the F factor (Hayes, 1953) E. coli EC2, tested subsequently, also transferred resistance to E. coli K12 and to Salm. typhimurium. The R factors from E. coli ECI and EC2 determined resistance only to trimethoprim and sulphonamide and were fi-. The factor from Klebsiella KA1 conferred resistance to streptomycin, tetracycline, and chloramphenicol as well as to trimethoprim and sulphonamide; it was fi +. K12 strains to which resistance was transferred from EC1 and EC2 were always resistant to both trimethoprim and sulphonamide no matter which of these drugs was used for selection. With the R factor from KA1 all five resistance markers (S, T, C, Su, TMP) were transferred together when either trimethoprim or sulphonamide or chloramphenicol was used for selection (Table I) Examinations of the rectal flora of all the other patients in the ward were performed by picking 10 lactose-fermenting colonies from a rectal swab culture from each and testing these for resistance to trimethoprim. One resistant colony was found among the 270 strains thus examined. This derived from a woman aged 86. She had been treated with trimethoprimsulphonamide in January. A month later she had developed an infection of the urinary tract with Kl. aerogenes, which was resistant to trimethoprim. This had responded to treatment. She had subsequently received a variety of courses of chemotherapy for unrelated conditions, including a further course of trimethoprim-sulphonamide. The single trimethoprim-resistant colony (EC2) proved to be E. coli 018, the same type as ECI above. Examination of ward records showed that in a threemonth period six courses of trimethoprim-sulphonamide had been given to patients in that ward.
KAI was isolated from the urine of an 80-year-old man who had been admitted to the hospital in October 1971. He had not previously received trimethoprim-sulphonamide but had been treated with a variety of other antibacterial agents.
PREVALENCE OF TRIMETHOPRIM RESISTANCE
Among 280 cultures of enteric bacteria isolated from cases of urinary infection in general practice 2 1% were resistant to trimethoprim and 20-7% to sulphonamide. For 309 hospital cultures these figures were 7-4% and 27-5% respectively. The higher frequency of resistance to trimethoprim among the hospital strains is largely accounted for by the greater number of urinary infections in hospital caused by Klebsiella spp., in which trimethoprim resistance is common (33%) ( Table II) . Davies, and Rownd 1972) . Such enzymes may possibly have evolved to protect bacteria against naturally occurring antibiotics. But the R factors first identified, as well as many recognized later all over the world, give resistance to sulphonamides as well as to antibiotics. The mechanism of R-factor-mediated sulphonamide resistance is not known. Can it have evolved since the first use of sulphonamides in the 1930s ? It seems unlikely. More probably a biochemical mechanism protective against sulphonamides already existed, evolved in response to unknown pressures, and was selected and encouraged to spread by the medical use of sulphonamides. Previously known R factors carrying genes for sulphonamide resistance do not, in our experience, confer resistance to trimethoprim. Lebek and Wiedmer (1971) and Lebek (personal communication) found, however, that some such R factors conferred a low level of trimethoprim resistance. The R factors we describe here give resistance to both drugs (as well as, in one case, to unrelated antibiotics). We do not know whether separate genes control resistance to the two synthetic drugs or whether a single biochemical mechanism gives resistance to both.
Resistance to trimethoprim was found in 1% of strains of E. coli isolated in 1966 from urinary infections in general practice two years before the drug became generally available for medical use. The prevalence of trimethoprim resistance in clinical isolates of E. coli remains at about this level in both hospital and domiciliary practice (Gruneberg, 1971) . The prevalence of trimethoprim resistance in Klebsiella spp. in hospital is higher (33%) than in E. coli. It is not known how much of the trimethoprim resistance at present found in enteric bacteria is R-factor determined.
The widespread use of trimethoprim may encourage the spread of such R factors, but up until now no such spread has become apparent in E. coli. R factors giving resistance, especially to streptomycin, the tetracyclines, and sulphonamides, are common in the normal bacteria of the human intestine (Datta, 1969; Datta et al., 1971) . All these drugs have been in use for over 20 years. Infections caused by bacteria resistant to them occur, and the proportion of R+ urinary infections outside hospital has increased, though not appreciably so, during the past decade (Shaw et al., 1972; Gillespie et al., 1971 ). What will happen in respect of trimethoprim-resistant R factors can at present only be a matter for speculation. We hope that clinical bacteriologists will monitor and report any changes which may occur in the usefulness of this valuable drug.
Salm. typhimurium WM 0024 was kindly supplied by Dr. J. R. Walton.
attached to red cells, which are then either directly agglutinated by anti-penicillin antibody or, if the antibody is weak, shown by a positive indirect Coombs test; and (3) the Aldomet (methyldopa) type, in which methyldopa either alters the red cell membrane or affects the antibody-forming tissues so that an autoantibody is produced which has a specificity within the rhesus blood group system. The drug takes no part in the serological reaction. Robinson and Faodi (1969) distinguished a fourth or cephalothin type; cephalothin, however, probably operates by mechanisms 1 and 2.
We here report the case of a patient with an immune haemolytic anaemia associated with tolbutamide, a sulphonylurea compound, and phenacetin.
Case Report
The patient, an Italian woman aged 58, presented with a history of lassitude, dyspnoea, headaches, and weakness of the legs for four weeks. Routine blood tests on 9 July 1971 showed haemoglobin 7-4 g/100 ml, P.C.V. 22%, M.C.H.C. 33%, and reticulocytes 30-5%. A blood film showed pronounced anisocytosis, poikilocytosis, and polychromasia, with normal white cell morphology. Haemolytic anaemia was suspected. She was admitted to hospital on 11 July and on examination appeared anaemic.
There was no evidence of bruising, lymphadenopathy, splenomegaly, or hepatomegaly, and the finger-nails were normal. Her pulse rate was 90/min and regular, blood pressure 130/90, and there were no other appreciable clinical features. A full blood investigation on 14 July showed: haemoglobin 7-8 g/100 ml;
